Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

Investigational Site Number : 1000003, Sofia

Investigational Site Number : 1000001, Sofia

Investigational Site Number : 1000002, Pleven

Investigational Site Number : 8040005, Vinnytsia

Investigational Site Number : 7920004, Eskişehir

The Neurological Institute Site Number : 8400004, Charlotte

Investigational Site Number : 7920002, Mersin

University of South Florida Site Number : 8400001, Tampa

Investigational Site Number : 7920003, Istanbul

Investigational Site Number : 7240002, Vigo

Investigational Site Number : 7920001, İzmit

Investigational Site Number : 2760004, Münster

Investigational Site Number : 8040010, Dnipro

Investigational Site Number : 8040006, Dnipro

Investigational Site Number : 2030002, Hradec Králové

Medical College of Wisconsin- Site Number : 8400006, Milwaukee

Investigational Site Number : 2030001, Jihlava

Investigational Site Number : 2500006, Calais

Investigational Site Number : 8040003, Odesa

Investigational Site Number : 2030003, Brno

Investigational Site Number : 2030005, Ostrava - Poruba

Investigational Site Number : 8040008, Ivano-Frankivsk

Investigational Site Number : 8040004, Lviv

Center for Neurology and Spine- Site Number : 8400007, Phoenix

Investigational Site Number : 6430007, Moscow

Investigational Site Number : 6430006, Moscow

Investigational Site Number : 6430001, Moscow

Investigational Site Number : 6430003, Saint Petersburg

Investigational Site Number : 6430005, Saint Petersburg

Investigational Site Number : 6430004, Saint Petersburg

Investigational Site Number : 6430002, Kazan'

Investigational Site Number : 6430008, Tyumen

Investigational Site Number : 1240001, Gatineau

Investigational Site Number : 2030004, Teplice

Investigational Site Number : 2760012, Leipzig

Investigational Site Number : 7240004, Barcelona

Investigational Site Number : 8040002, Kyiv